EATG » Scientific research

Scientific research

Chinese scientist claims to have edited embryos to make children HIV resistant

A pair of twin girls have been born as a part of his efforts, greatly alarming the worldwide research community. Sparking considerable controversy, a Chinese researcher claims to have edited…

Scripps Research scientists unveil promising new HIV vaccine strategy

LA JOLLA, CA – A new candidate HIV vaccine from Scripps Research surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests.…

Majority of HIV persistence during ART due to infected cell proliferation, not viral replication

Study confirms biological mechanism responsible for latent HIV reservoirs; suggests strategies for a functional HIV cure SEATTLE — Nov. 16, 2018 — A majority of the HIV-infected cells that persist…

HIV latency differs across tissues in the body

Mechanisms that govern HIV transcription and latency differ in the gut and blood, according to a study published November 15 in the open-access journal PLOS Pathogens by Steven Yukl of…

Novel mechanism of immune activation in HIV-exposed, seronegative people who inject drugs

PHILADELPHIA — (Nov. 13, 2018) — According to new research from The Wistar Institute, the S100A14 protein is expressed at higher levels in people who inject drugs and remain uninfected despite…

Research reveals details of how HIV becomes infectious

HIV, the virus that causes AIDS, has been studied extensively ever since the AIDS epidemic was officially recognized by health professionals in the early 1980s. During that time, research has…

IAVI and Serum Institute of India to develop and manufacture globally affordable and accessible antibody products for HIV

NEW YORK – October 22, 2018 – The International AIDS Vaccine Initiative (IAVI) and Serum Institute of India, the world’s largest vaccine manufacturer, today announced a strategic partnership to develop and…

AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement to evaluate a therapeutic vaccine and TLR7 agonist regimen for HIV cure

AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like Receptor 7 agonist vesatolimod (GS-9620) in HIV-infected individuals BARCELONA, Spain, October 18, 2018:…

New light shed on HIV-1 reservoir reductions after stem cell transplant

Several factors underlie a profound reduction in the HIV-1 reservoir in patients who undergo allogeneic hematopoietic stem cell transplant (allo-HSCT) for hematologic disease, researchers report. Previous studies have found substantial…

Not all people are equally vulnerable to hepatitis C – new study

The hepatitis C virus (HCV) infects around 1% of the human population and is a devastating pathogen. In most people, it silently infects the liver for decades, often causing life-threatening…